Gene Replacement for RPE65-Mediated Inherited Retinal Dystrophy
By Lynda Seminara
Selected By: Deepak P. Edward, MD
Journal Highlights
Lancet
Published online July 13, 2017
Download PDF
Building on evidence of the potential benefit of gene replacement for RPE65-mediated inherited retinal dystrophy, Russell et al. evaluated voretigene neparvovec in patients whose retinal dystrophy would cause complete blindness if untreated. They found that gene replacement with the AAV2 vector was safe and effective.
For this open-label, randomized phase 3 trial, the researchers enrolled 31 patients who were ≥ 3 years of age at 2 sites in the United States. Participants had a best-corrected visual acuity (BCVA) of 20/60 or worse in each eye and/or a visual field < 20 degrees in any meridian as well as a confirmed genetic diagnosis of biallelic RPE65 mutations. All participants were required to have sufficient viable retinal cells and to perform a standardized multiluminance mobility test (MLMT) within the luminance range evaluated.
Of the 31 patients, 21 were randomly assigned to the intervention arm; the remaining 10 were assigned to the control arm. Treatment consisted of bilateral subretinal injection (1.5 × 1011 vector genomes of voretigene neparvovec in 0.3 mL total volume). The primary efficacy outcome was the 1-year change in MLMT performance, with functional vision measured at specified light levels.
The mean bilateral change in MLMT score from baseline to one year was 1.8 light levels in the intervention group and 0.2 light levels in the control group. Thirteen (65%) of the 20 intervention participants and none of the controls passed the MLMT at 1 lux, demonstrating that maximum possible improvement was achieved in those 13 patients. No serious adverse events related to the study treatment occurred, and there were no deleterious immune responses. Most adverse ocular events were mild.
The original article can be found here.